Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | NNMT | P40261 | 1/20 | 0.53 |
| ▸ | ADK | P55263 | 5/20 | 0.53 |
| ▸ | METTL3 | Q86U44 | 11/20 | 0.49 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419136 | 0.87 | ADK (0.59) | ADKMETTL3RAPGEF3 | |
| SCHEMBL20419234 | 0.87 | ADK (0.59) | ADKMETTL3RAPGEF3 | |
| SCHEMBL20938262 | 0.87 | ADK (0.59) | ADKMETTL3RAPGEF3 | |
| SCHEMBL20938368 | 0.81 | ADK (0.57) | PRMT5ADKMETTL3 | |
| SCHEMBL20917712 | 0.78 | ADK (0.67) | PRMT5ADKMETTL3RAPGEF3 | |
| SCHEMBL20938240 | 0.77 | ADK (0.53) | PRMT5ADKMETTL3RAPGEF3 | |
| SCHEMBL24293515 | 0.75 | ADK (0.57) | PRMT5ADKMETTL3RAPGEF3 | |
| SCHEMBL14305600 | 0.75 | ADK (0.60) | ADKMETTL3RAPGEF3 | |
| SCHEMBL20938333 | 0.74 | ADK (0.46) | DOT1LPRMT5ADKMETTL3 | |
| SCHEMBL22912603 | 0.74 | PRMT5 (0.48) | DOT1LPRMT5ADKMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | UNIVERSITEIT GENT (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT GENT (BE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | PNP, NUDT1, SAMHD1 | DOT1L 1419/4885PRMT5 716/4885PRMT3 1075/4885 |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | PNP, NUDT1, SAMHD1 | DOT1L 1419/4885PRMT5 716/4885PRMT3 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.